Big pharma ' s blockbuster obesity drug battle is just getting started, and it ' s headed for $100 billion

In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo's Ozempic and Wegovy and Lilly's Mounjaro, news of a study…#novonordisk #elililly #novoozempicand #wegovyandlilly #mounjaro #wegovy #pfizer #amgen #novo #lilly
Source: Reuters: Health - Category: Consumer Health News Source Type: news